This application is a competitive renewal for RO1 HL62526: """"""""Myeloperoxidase, Oxidant Stress and Atherogenesis."""""""" Four years ago we hypothesized that monocytes use myeloperoxidase (MPO) to generate species that contribute to oxidative stress, cellular injury and conversion of LDL into an atherogenic form. During the conduct of this research we demonstrated mechanisms of how leukocyte MPO may participate in host defenses, inflammatory injury, and atherosclerosis. Despite the many links between MPO, oxidant stress, and coronary artery disease (CAD), many critical questions remain. For example, direct demonstration of a causal role for the enzyme in disease development and progression remains to be established. Further, the role of oxidation in atherogenesis has recently been questioned based upon the failure of multiple """"""""antioxidant"""""""" trials. The present proposal is both an extension of our earlier research, and a direct effort to address these questions. It is predicated upon the hypothesis that MPO and oxidative stress are mechanistically linked to the development of cardiovascular disease. It integrates studies on basic mechanisms with a search for specific reaction products that reveal whether relevant pathways operate in human disease, and in animal models of inflammation. In preliminary studies we present evidence for a novel catalytic activity for MPO which may enable the enzyme to participate in endothelial dysfunction in CAD. We demonstrate pathways through which MPO catalysis leads to formation of reactive aldehydic intermediates that are cytotoxic and implicated in atherogenesis. We demonstrate that MPO and systemic measures of its activity are linked to atherosclerotic risk and oxidant stress in vivo. The overall goals of this proposal are to: (i) provide mechanistic insights into novel pathways of MPO catalysis and function; (ii) test the hypothesis that MPO generates cytotoxic aldehydes that promote cellular injury and oxidant stress in vivo; and (iii) use a combination of genetic and biochemical approaches to define the role of MPO and specific oxidation pathways in development of cardiovascular disease in humans. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL062526-05
Application #
6614364
Study Section
Metabolism Study Section (MET)
Program Officer
Srinivas, Pothur R
Project Start
1999-05-01
Project End
2004-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
5
Fiscal Year
2003
Total Cost
$372,500
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
017730458
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Lu, Qiuya; Yang, Likui; Manithody, Chandrashekhara et al. (2015) Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients. Biochemistry 54:3814-21
Ma, Yina; Wang, Jinli; Gao, Junjie et al. (2015) Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury. Thromb Haemost 113:338-49
Shishehbor, Mehdi H; Zhang, Renliang; Medina, Hector et al. (2006) Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 41:1678-83
Anning, Peter B; Coles, Barbara; Bermudez-Fajardo, Alexandra et al. (2005) Elevated endothelial nitric oxide bioactivity and resistance to angiotensin-dependent hypertension in 12/15-lipoxygenase knockout mice. Am J Pathol 166:653-62
Nicholls, Stephen J; Shen, Zhongzhou; Fu, Xiaoming et al. (2005) Quantification of 3-nitrotyrosine levels using a benchtop ion trap mass spectrometry method. Methods Enzymol 396:245-66
Vadseth, Caryn; Souza, Jose M; Thomson, Leonor et al. (2004) Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem 279:8820-6
Zheng, Lemin; Nukuna, Benedicta; Brennan, Marie-Luise et al. (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114:529-41
Milla, Carlos; Yang, Shuxia; Cornfield, David N et al. (2004) Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol 287:L706-14
Moore, David F; Ye, Frank; Brennan, Marie-Luise et al. (2004) Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 20:674-83
Vita, Joseph A; Brennan, Marie-Luise; Gokce, Noyan et al. (2004) Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110:1134-9

Showing the most recent 10 out of 45 publications